Home About Cytheris Corporate Overview Executive Management Board of Directors Clinical Advisory Board Academic Partners History Science Pipeline & Products Development Pipeline IL-7 in Oncology IL-7 in HIV IL-7 in HBV IL-7 in HCV Intellectual Property Manufacturing Clinical Trials Clinical Trials Overview IL-7 Oncology Trials IL-7 HIV Trials IL-7 HBV Trials IL-7 HCV Trials Other IL-7 Trials Business Development News Room Press Releases Calendar of Events Investors Careers Contact Us

DOWNLOAD CORPORATE FACT SHEET (PDF)

Corporate Overview

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation.  These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

The company's lead compound, recombinant human Interleukin-7 (r-hIL-7), is a critical growth factor for immune T cell recovery and enhancement. Clinical trials conducted on more than 140 patients in Europe, North America and Taiwan have demonstrated a consistent safety and tolerability profile as well as the potential of IL-7 to expand and protect CD4+ and CD8+ T-cells in various pathologic conditions.

Currently, Cytheris is conducting multiple international investigations of IL-7 in HIV, HBV, HCV, idiopathic CD4 lymphocytopenia (sponsored by NIAID/NIH) and cancer, the latter including an NCI/NIH-sponsored study of IL-7 in combination with dendritic cell vaccines in a pilot study of tumor vaccination in children, and a study designed to restore CD4+ and CD8+ counts following T-cell depletion due to bone marrow or peripheral blood stem cell transplant (being conducted at the Memorial Sloan-Kettering Cancer Center in New York City).

The company operates from its headquarters and laboratories in Issy-les-Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland.